Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny has then
Moved to the United States, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
During his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical themes, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer on a clinical phase I/II
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Mikhail Blagosklonny published many of experimental research papers and theoretical articles as sole
Author. Those sole-author papers
Discussed two important topics.
The first of these discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Validation their resistance. The results and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the paper was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research methodology to come up with knowledge by
Bringing a few facts together from seemingly unrelated fields.
This results in new concepts containing testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Important outcome discovered by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others can’t even see. ”
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Preventing organism aging — in other words, “preventing cancer
By staying young. ” His lab closely worked together with
Andrei Gudkov’s and completed research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of additional anti-aging
Medications beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models like
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging drugs to be taken by humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.